Journal Manager Demo for Scholarly Journals
Aims and Scope
What This Journal Publishes
A peer-reviewed, open-access journal for the genomic and epigenomic drivers of cancer — from mechanism through to clinical translation.
Our Aim
We publish work that advances understanding of how genomic and epigenomic change drives malignancy, and how that understanding reaches patients. We value methodological rigour and reproducibility over novelty for its own sake, and we actively seek negative and confirmatory results where they are well powered. A study that closes a question is as valuable to us as one that opens it.
Subject Areas
Discovery
Tumour evolution, epigenetic regulation, structural variation, single-cell and spatial genomics.
Translation
Biomarkers, liquid biopsy, early detection, therapeutic resistance and precision oncology.
Methods
Sequencing chemistry, computational pipelines, benchmarking studies and open analytical tooling.
Populations
Germline risk, ancestry-aware analysis, screening programmes and health-system implementation.
In Scope
- Genome-wide and targeted studies of carcinogenesis and tumour progression
- Epigenetic mechanisms including methylation, chromatin state and non-coding regulation
- Single-cell, spatial and long-read approaches to tumour heterogeneity
- Circulating tumour DNA and other minimally invasive diagnostics
- Functional genomics, including CRISPR screens and synthetic-lethal interactions
- Computational methods released with documented, runnable code
- Germline and polygenic contributions to cancer susceptibility
- Pharmacogenomics and mechanisms of acquired treatment resistance
- Tumour–immune interaction where a genomic or transcriptomic readout is central
- Benchmarking and reproducibility studies of established methods
Out of Scope
- Case reports without a genomic or molecular component
- Purely clinical trials with no accompanying molecular analysis
- Re-analyses of public data that add no new interpretation
- Studies where the underlying data cannot be shared
- Cell-line-only work with no validation in primary material
- Predictive models reported without an independent test set
Article Types
Research Article
Full-length original work. No fixed word limit; length should match the evidence.
Brief Report
A single, well-supported finding. Up to 2,500 words and three display items.
Review
Commissioned or proposed. Send an outline before writing a full submission.
Registered Report
Peer-reviewed before results exist; acceptance in principle survives the outcome.
Readership
Our readers are cancer biologists, computational scientists, pathologists and clinical oncologists. Write so that a competent researcher one field away can follow the argument: define abbreviations on first use, state what is new in the abstract, and keep the methods detailed enough to be repeated.
Ready to submit?
Read the Guide for Authors, then start your submission from the Submit Paper menu.